Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neurofibromatosis 2 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma, Malignant 1Medulloblastoma 1Lethal Congenital Contracture Syndrome 2 1Hemangiosarcoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 115Carboplatin 114Cisplatin 46Topotecan 43Gemcitabine 31Cyclophosphamide 31Docetaxel 28Bevacizumab 28liposomal doxorubicin 27Filgrastim 20pembrolizumab 19Peripheral Blood Stem Cell Transplantation 18Taxes 15Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 13sargramostim 12olaparib 12Immunohistochemistry 11Chemotherapy, Adjuvant 11Surgical Procedures, Operative 10Therapeutics 9Flow Cytometry 9Etoposide 9oregovomab 8niraparib 8mirvetuximab soravtansine 8Psychiatric Rehabilitation 8Nivolumab 8Amifostine 8rucaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Vascular Endothelial Growth Factor A × Clear all
NCT01551745 2021-10-19

Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab

Gradalis, Inc.

Phase 2 Completed
5 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡